Literature DB >> 20825403

Comparison of lymph node yield in robot-assisted laparoscopic prostatectomy with that in open radical retropubic prostatectomy.

Costas D Lallas1, Mark L Pe, Adeep B Thumar, Thenappan Chandrasekar, Franklin C Lee, Peter McCue, Leonard G Gomella, Edouard J Trabulsi.   

Abstract

OBJECTIVE: • To investigate both the feasibility and the adequacy of pelvic lymph node dissection (PLND) during robot-assisted laparoscopic prostatectomy (RALP) by comparing lymph node yields obtained during RALP with those obtained during traditional open retropubic radical prostatectomy (RRP). PATIENTS AND METHODS: • We retrospectively reviewed 1047 patients who underwent radical prostatectomy between 2001 and 2009. • In all, 626 patients underwent RALP while 421 patients had traditional open RRP. All patients undergoing bilateral PLND were included in our analysis. • Lymph node yields and lymph node involvement for each surgical approach were calculated and examined. • PLND-related complications were analysed.
RESULTS: • Of the 1047 patients, 816 patients underwent bilateral PLND of whom 473 underwent RALP, while 343 underwent RRP. The mean lymph node yields for the RALP cohort (7.1, interquartile range 4-10) was significantly higher (P < 0.001) than for the RRP cohort (6.0, interquartile range 3-8). • The percentage of patients with nodal involvement was 1.1 for RALP and 2.3 for RRP (P= 0.167). • Mean age, preoperative PSA values, and pre- and postoperative Gleason scores were similar between the two cohorts. • PLND-related complications were similar between both cohorts.
CONCLUSIONS: • In patients undergoing RALP, PLND is feasible and provides lymph node yields comparable with those of the standard open approach. • PLND should be strongly considered in all radical prostatectomy patients when clinically indicated, regardless of surgical technique.
© 2010 THE AUTHORS. BJU INTERNATIONAL © 2010 BJU INTERNATIONAL.

Entities:  

Mesh:

Year:  2010        PMID: 20825403     DOI: 10.1111/j.1464-410X.2010.09621.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  8 in total

1.  Prostate cancer: Robotic debate dampened by long-term data?

Authors:  Suzanne J Farley
Journal:  Nat Rev Urol       Date:  2010-11       Impact factor: 14.432

2.  Topographical relationships between the obturator nerve, artery, and vein in the lateral pelvic wall.

Authors:  Hyung-Sun Won; Jun-Ho Kim; U-Young Lee; Koon Ho Rha; Dae Keun Kim
Journal:  Int Urogynecol J       Date:  2015-07-30       Impact factor: 2.894

Review 3.  Reducing morbidity of pelvic and retroperitoneal lymphadenectomy.

Authors:  Mark W Ball; Michael A Gorin; Mohamad E Allaf
Journal:  Curr Urol Rep       Date:  2013-10       Impact factor: 3.092

Review 4.  Quality of evidence to compare outcomes of open and robot-assisted laparoscopic prostatectomy.

Authors:  Branden Duffey; Briony Varda; Badrinath Konety
Journal:  Curr Urol Rep       Date:  2011-06       Impact factor: 3.092

Review 5.  Complications of pelvic lymph node dissection for prostate cancer.

Authors:  K A Keegan; M S Cookson
Journal:  Curr Urol Rep       Date:  2011-06       Impact factor: 3.092

6.  Microbiological evaluation of infected pelvic lymphocele after robotic prostatectomy: potential predictors for culture positivity and selection of the best empirical antimicrobial therapy.

Authors:  Alaa Hamada; Catalina Hwang; Jorge Fleisher; Ingolf Tuerk
Journal:  Int Urol Nephrol       Date:  2017-04-24       Impact factor: 2.370

Review 7.  Comparison of Robot-Assisted Radical Prostatectomy and Open Radical Prostatectomy Outcomes: A Systematic Review and Meta-Analysis.

Authors:  Hyun Ju Seo; Na Rae Lee; Soo Kyung Son; Dae Keun Kim; Koon Ho Rha; Seon Heui Lee
Journal:  Yonsei Med J       Date:  2016-09       Impact factor: 2.759

Review 8.  Current technique and results for extended pelvic lymph node dissection during robot-assisted radical prostatectomy.

Authors:  Roger Li; Firas G Petros; Janet B Kukreja; Stephen B Williams; John W Davis
Journal:  Investig Clin Urol       Date:  2016-12-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.